Lessons learned from the metastatic castration-resistant prostate cancer phase I trial of EPI-506, a first-generation androgen receptor N-terminal domain inhibitor

Abstract only 257 Background: Aniten compounds bind to the N-terminal domain (NTD) of the androgen receptor (AR) and inhibit AR dependent transcription. EPI-506, the pro-drug of EPI-002, was the first AR NTD inhibitor tested in a Phase 1 study in men with metastatic castration-resistant prostate can...

Full description

Bibliographic Details

Published in:	Journal of clinical oncology Vol. 37; no. 7_suppl; p. 257
Main Authors:	Le Moigne, Ronan, Zhou, Han-Jie, Obst, Jon K., Banuelos, C. Adriana, Jian, Kunzhong, Williams, David, Virsik, Peter, Andersen, Raymond J, Sadar, Marianne, Perabo, Frank, Chi, Kim N.
Format:	Journal Article
Language:	English Japanese
Published:	01-03-2019
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!